Form 4: FibroBiologics Chief Scientific Officer Granted Stock Options

Hamid Khoja, Chief Scientific Officer of FibroBiologics, Inc., was granted options to purchase 189,000 shares of common stock on March 26, 2025.

Summary

• On March 26, 2025, Hamid Khoja, the Chief Scientific Officer of FibroBiologics, Inc., received stock options.
• The options grant him the right to purchase 189,000 shares of the company's common stock at an exercise price of $1.04 per share.
• The options vest over a period of four years, with one-fourth vesting on the first anniversary of the grant date and the remaining balance vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant suggests confidence in the executive and the company's future, leading to a slightly positive sentiment.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of FibroBiologics' stock price, which is subject to market risks and company-specific factors.
• If the stock price does not appreciate above the exercise price of $1.04, the options may not be valuable to the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant (189,000 shares) and the vesting schedule (25% after one year, then monthly) are typical for a Chief Scientific Officer role in a company of FibroBiologics' size and stage.
• Comparable companies in the regenerative medicine space often use similar equity-based compensation to incentivize key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
• Employees may be motivated by the fact that key executives are incentivized to improve the company's performance.

Key Dates

Keywords

stock options, FibroBiologics, Hamid Khoja, Chief Scientific Officer, equity compensation, vesting, FBLG